5.20
-0.03
(-0.57%)
May 17 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 5.16 - 5.24 |
| 52 week | 3.45 - 6.15 |
| Open | 5.24 |
| Vol / Avg. | 69,800.00/158,093.00 |
| Mkt cap | 152.77M |
| P/E | 168.72 |
| Div/yield | - |
| EPS | 0.03 |
| Shares | 29.38M |
| Beta | 1.07 |
| Inst. own | 61% |
Events
Jul 29, 2013
Q2 2013 Harvard Bioscience, Inc. Earnings Release
May 23, 2013
Harvard Bioscience, Inc. Annual Shareholder Meeting
- 11:00AM EDT -
May 2, 2013
Q1 2013 Harvard Bioscience, Inc. Earnings Conference Call
Apr 29, 2013
Q1 2013 Harvard Bioscience, Inc. Earnings Release
Feb 28, 2013
Q4 2012 Harvard Bioscience, Inc. Earnings Conference Call
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -0.32% | 1.38% |
| Operating margin | -0.61% | 2.85% |
| EBITD margin | - | 6.47% |
| Return on average assets | -0.25% | 1.18% |
| Return on average equity | -0.32% | 1.53% |
| Employees | 398 | - |
| Carbon Disclosure Rating | - | - |
Address
84 October Hill Road
HOLLISTON, MA 01746
United States - Map
+1-508-8938999 (Phone)
+1-508-4295732 (Fax)
HOLLISTON, MA 01746
United States - Map
+1-508-8938999 (Phone)
+1-508-4295732 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Harvard Bioscience, Inc. is a global developer, manufacturer and marketer of a range of specialized products, apparatus and scientific instruments, used to advance life science research at pharmaceutical and biotechnology companies, universities and government laboratories worldwide. The Company sells its products to thousands of researchers in over 100 countries through its 850 page catalog (and various other specialty catalogs), Website, through distributors, including GE Healthcare, Thermo Fisher Scientific Inc. and VWR, and via its field sales organization. The Company�s product range is targeted towards two application areas: ADMET testing and molecular biology. In February 1, 2012, the Company acquired the business of AHN Biotechnologie GmbH through its wholly owned subsidiary, Biochrom Ltd. In July 2011, it acquired the preclinical business unit of CMA Microdialysis AB.
Officers and directors
| David M. Green | President, Interim Chief Executive Officer, Director | |
| Thomas McNaughton Jr. | Chief Financial Officer, Treasurer | |
| Susan M. Luscinski | Chief Operating Officer | |
| Earl R. Lewis | Lead Independent Director | |
| Robert Dishman Ph.D. | Independent Director | |
| Neal J. Harte | Independent Director | |
| John F. Kennedy | Independent Director | |
| George Uveges | Independent Director |